TryGOLD- Free

Novo Nordisk's new obesity pill beats Wegovy in early trial
Financial Express Mumbai|March 08, 2024
NOVO NORDISK SAID on Thursday early trial data for its highly anticipated experimental obesity drug amycretin showed a higher weight loss compared with its popular Wegovy treatment, sending its shares to new record highs.
- JACOB GRONHOLT-PEDERSEN MAGGIE FICK
Novo Nordisk's new obesity pill beats Wegovy in early trial

A Phase I trial of amycretin pill version showed participants lost 13.1% of their weight after 12 weeks, the company said at an investor meeting. That compares to a weight loss of about 6% after 12 weeks in a trial for Wegovy, its blockbuster obesity drug.

Investors welcomed the news as indicating Novo had more in its pipeline beyond its hugely successful Wegovy. Its shares have soared since launching the weekly injections in the United States in 2021 and are now Europe's most valuable listed company, ahead of LVMH.

This story is from the March 08, 2024 edition of Financial Express Mumbai.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

Novo Nordisk's new obesity pill beats Wegovy in early trial
Gold Icon

This story is from the March 08, 2024 edition of Financial Express Mumbai.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM FINANCIAL EXPRESS MUMBAIView All
Financial Express Mumbai

Flipkart's Zero Commission Sparks Row

No discrimination, no violation, says e-commerce firm

time-read
2 mins  |
February 27, 2025
Financial Express Mumbai

Trump's USAID crackdown imperils global newsrooms

● Investigative journalists world over relied on US funding

time-read
2 mins  |
February 27, 2025
Financial Express Mumbai

Arunachal Pradesh can generate 50K MW of hydropower, says VP

ARUNACHAL PRADESH HAS the potential to generate 50,000 MW of hydropower, vice president Jagdeep Dhankhar said on Wednesday, maintaining that the state holds the key to India's energy future.

time-read
1 min  |
February 27, 2025
Financial Express Mumbai

Centre Opposes Poll Ban on Convicted Leaders

OPPOSING PETITIONS SEEKING a lifetime ban on convicted politicians from contesting elections, the Central government has submitted in the Supreme Court that there is \"nothing inherently unconstitutional\" in limiting their disqualification to six years.

time-read
2 mins  |
February 27, 2025
Financial Express Mumbai

Logistics firms’ share in e-comm shipments to rise 30% by FY29: Report

THIRD-PARTY LOGISTICS PLAYERS’ (3PLs) share of e-commerce shipments, excluding grocery, will continue to grow in line with the growth in online shipments over the next five years, according to a report by Redseer.

time-read
1 min  |
February 27, 2025
Financial Express Mumbai

Listing gains slow but steady

Investors get average 25% returns despite weaker markets

time-read
2 mins  |
February 27, 2025
Financial Express Mumbai

Airtel in talks with Tata Play for merger with Bharti Telemedia

BHARTI AIRTEL on Wednesday confirmed that it is in talks with the Tata Group over a potential merger of Tata Play with Bharti Telemedia.

time-read
1 min  |
February 27, 2025
Financial Express Mumbai

Isro's space launch foray

The communication satellite launch industry could be a catalyst for ISRO and NewSpace India Ltd becoming self-reliant and profitable

time-read
4 mins  |
February 27, 2025
Financial Express Mumbai

Nasdaq Leads Wall St Higher With Spotlight on Nvidia Results

THE TECH-HEAVY NASDAQ led Wall Street's main indices higher on Wednesday as chip stocks rebounded ahead of Nvidia's results that are crucial to illuminating future demand for AI.

time-read
1 min  |
February 27, 2025
Financial Express Mumbai

Trump floats $5-mn 'gold card' as a route to US citizenship

US PRESIDENT Donald Trump has floated the idea of replacing a visa programme for foreign investors with a so-called \"gold card\" that could be bought for $5 million as a route to American citizenship.

time-read
1 min  |
February 27, 2025

We use cookies to provide and improve our services. By using our site, you consent to cookies. Learn more